Daniel sent us this one — and honestly, it's one of those structural problems that just gnaws at you. Right now there are somewhere between seven thousand and ten thousand rare diseases, about thirty million Americans living with them, and roughly ninety-five percent still have no approved treatment. The core question is: governments have been trying to fix this market failure for decades now — orphan drug acts, tax credits, exclusivity extensions, priority review vouchers, patient registries — but which of these tools have actually moved the needle, and which ones created new problems nobody saw coming?
The tension here is fascinating because you have this collision between genuine humanitarian need and the brutal economics of drug development. I mean, when your potential patient population is measured in hundreds or thousands rather than millions, traditional R and D math just breaks. The Commonwealth Fund put out a really thorough analysis last November that laid this bare — in the entire decade before the U.Orphan Drug Act passed in nineteen eighty-three, there were only thirty-four orphan drugs on the market. And ten of those were developed by the federal government, not by pharmaceutical companies.
Ten out of thirty-four. So the private sector basically wasn't showing up.
And this is the starting point for understanding why the Orphan Drug Act was genuinely revolutionary. It created four core incentives. Seven years of market exclusivity for the orphan indication, tax credits for clinical trial costs — originally fifty percent, though that got cut to twenty-five percent in twenty seventeen — exemption from F.user fees, which are now nearly three million dollars per application, and direct research grants for clinical trials. And the results are hard to argue with. Since passage, the F.has approved nearly eight hundred drugs through the orphan drug pathway.
Eight hundred drugs from a baseline of thirty-four. That's not incremental improvement, that's a completely different world. But here's where my skepticism kicks in — and I know you've dug into the Health Affairs data on this — how much of that success is actually attributable to the exclusivity provision versus the other incentives?
This is exactly the right question, and the Health Affairs study that looked at data from nineteen eighty-five through twenty fourteen is surprising. They found that orphan drug exclusivity outlasted patents in only thirty-three percent of cases overall. But the trend line is what really matters — that share dropped from fifty percent in the early cohort to just eighteen percent in the two thousand five to twenty fourteen period. Exclusivity contributed only seventeen percent of total market exclusivity across the full period. It was thirty percent early on, then dropped to seven percent later.
The thing that gets the most political attention — this fight over exclusivity length — might not actually be the primary driver of the surge in approvals.
That's the implication. Patents are doing most of the work. Which raises the question of whether policymakers should be spending their political capital fighting over exclusivity periods when tax credits, grant funding, and voucher programs might be more effective levers. And speaking of vouchers — this is actually a really bright spot. The Rare Pediatric Disease Priority Review Voucher program has awarded sixty-three vouchers since twenty twelve, leading to treatments for forty-seven rare pediatric diseases, forty-three of which had no prior F.-approved treatment at all.
Oh, and by the way — DeepSeek V four Pro is writing our script today, so if anything sounds unusually coherent, that's why.
I'll take that as a compliment to our usual baseline. But back to the vouchers — these things sell for roughly a hundred million dollars on the open market. That's a real funding mechanism. A small biotech that develops a treatment for an ultra-rare pediatric condition can essentially monetize that voucher to fund their next round of research. And the program just got reauthorized through September twenty twenty-nine as part of the Consolidated Appropriations Act signed in February.
A hundred million dollars for what is essentially a piece of paper that says "expedite this review." That's a market signal if I've ever seen one.
It's working well enough that the F.launched a related pilot — the Commissioner's National Priority Voucher program — which just achieved a sixty-one day Biologics License Application approval for a gene therapy targeting genetic hearing loss. That's the fastest in modern F.
Sixty-one days. For context, what's a normal review timeline?
Standard review is ten months, priority review is six months. So sixty-one days is, frankly, unprecedented. But this brings us to the bigger question about what we're actually incentivizing, because the orphan drug story isn't all triumph. There's something researchers call the "orphan paradox," and it's where things get complicated.
This is the part where drugs for tiny patient populations somehow become blockbusters.
The Commonwealth Fund analysis found that the average annual price for a non-orphan drug was twenty-three thousand dollars versus a hundred and eighteen thousand for an orphan drug — roughly five times higher. And a more recent study put the gap even wider, with orphan-indication drugs averaging two hundred eighteen thousand dollars annually per patient versus twelve thousand eight hundred for non-orphan drugs. In twenty twenty-four, the three highest-priced new drugs all targeted rare diseases, with list prices exceeding three point five million dollars each.
Three point five million dollars per patient per year. That's not a healthcare cost, that's a real estate purchase.
Here's the paradox — five-year net sales for drugs first approved for an orphan indication averaged seven hundred nineteen million dollars. That's nearly as lucrative as non-orphan drugs with an orphan indication at eight hundred twelve million. About twenty percent of drugs are approved for both orphan and non-orphan indications, and roughly one-third of those are among the top-selling drugs in the world.
You've got drugs that started with an orphan designation but then expanded into massive common-disease markets, still benefiting from the orphan incentives. That's the AbbVie Humira playbook, right?
Humira is the poster child. AbbVie used orphan designations to extend exclusivity on what became the best-selling drug in history. Merck did it with Keytruda, Amgen with Enbrel, Genentech with Avastin. An analysis found that for drugs with both orphan and non-orphan indications, only twenty-one percent of spending was for the orphan use — seventy-one percent was for non-orphan indications. So the question becomes: should a drug that makes billions from common diseases still qualify for orphan incentives?
It feels like the system was designed for a small biotech trying to keep the lights on while developing a treatment for a disease that affects three hundred people, not for a multinational pharma giant protecting a franchise worth tens of billions.
This tension gets even sharper when you look at what the Inflation Reduction Act has done to orphan drug development. 's drug price negotiation program exempts orphan drugs — but only for a single orphan indication. If a drug wins a second orphan designation, it becomes eligible for price negotiation.
Wait, so the incentive structure actually punishes companies for pursuing additional rare disease indications?
That's exactly what's happening. The National Pharmaceutical Council did an analysis and found that the percentage of orphan drugs receiving a second designation dropped by forty-eight percent after twenty twenty-two. And there's a concrete example that really drives this home. Alnylam canceled a planned Phase Three trial of vutrisiran in Stargardt disease in October twenty twenty-two specifically because pursuing a second orphan indication could expose Amvuttra — which generated nine hundred seventy million dollars in twenty twenty-four revenue — to price negotiation.
A company looked at a rare retinal disease that causes vision loss in children and young adults, had a drug that might help, and said "we can't pursue this because the financial risk to our existing business is too great." That's not a hypothetical market failure — that's a government-created market failure layered on top of the original one.
The fix — the ORPHAN Cures Act, which would expand the exemption to cover multiple orphan indications — was included in the House version of the twenty twenty-five reconciliation bill but got dropped from the Senate version. The Congressional Budget Office estimated the provision could cost the federal government nearly eight point eight billion dollars in lost Medicare savings over ten years.
Eight point eight billion dollars is real money. But you have to weigh that against the cost of leaving rare diseases untreated — which is harder to quantify but no less real. What's the cost of a child going blind from Stargardt disease because the company that might have developed a treatment decided the regulatory risk wasn't worth it?
This is the fundamental tension that runs through all rare disease policy. Every incentive you create to spur innovation also creates opportunities for gaming. Every cost containment measure you implement risks chilling development. And it's not just a U.problem — the European Union has been grappling with its own version of this for decades.
model is interesting because they went with longer exclusivity — ten years versus seven in the U.— but they've got this fragmentation problem that the U.doesn't have to deal with.
The European Medicines Agency provides centralized approval, but then reimbursement decisions happen at the national level. Each country negotiates its own pricing. In France, the median time from marketing authorization to reimbursement is three hundred sixty days, and seventy-one percent of access delays are caused by these pricing and reimbursement discussions. So you can have an approved drug that patients can't actually get for a year or more while bureaucrats haggle over the price.
is now considering variable exclusivity — nine years standard, eleven years for breakthrough therapies, potentially as little as four or five years for well-established-use products. Is that going to help or just add more complexity?
The intent is to better target incentives — give more protection to drugs that represent breakthroughs, less to drugs that are repurposing known compounds. But the practical effect might be to make the regulatory landscape even harder for small companies to navigate. Big pharma can afford regulatory affairs teams that track all this. A ten-person biotech in Lyon probably can't.
One thing I've been wondering about — and I know you've looked at this — is how other countries handle this. We've talked about the U.and Europe, but what about Japan, China, places with different healthcare systems and different political pressures?
Japan adopted its own orphan drug framework following the U.precedent, and it's been reasonably effective, though the comparative data is more limited. China is the interesting case because their incentive framework scores lowest on basically every dimension — R and D funding support, clinical trial incentives, patient and social support. And they haven't effectively addressed the social discrimination and employment barriers that rare disease patients face. So you have a policy framework that's underdeveloped on the drug development side and essentially absent on the patient support side.
That tracks with what we know about how China's regulatory state operates — they've been playing catch-up on a lot of these frameworks. But it also highlights something that I think gets lost in the exclusivity debates: the non-financial barriers matter enormously. Patient registries, natural history studies, diagnostic infrastructure — these are the unglamorous pieces that make everything else possible.
This is actually where I think some of the most promising work is happening. Patient registries and natural history studies provide longitudinal real-world data on disease progression, phenotypic diversity, and suitable trial populations. When your patient population is too small for traditional randomized controlled trials, you need this infrastructure to even know who your patients are and how the disease behaves. Germany has been using real-world evidence in pricing negotiations and it's reduced orphan-drug approval delays by twenty-five percent.
Twenty-five percent faster access because you built the data infrastructure. That's the kind of policy intervention that doesn't make headlines but actually changes outcomes.
is moving in this direction too. They launched a Rare Disease Innovation Hub in twenty twenty-four, and it got a million dollars in dedicated funding for twenty twenty-six. They're planning these RISE workshops on data sharing and patient voice in drug development. It's not flashy, but it's the kind of foundational work that makes everything else work better.
There's another piece of this that I want to pull on — the gene therapy funding collapse. You mentioned the numbers earlier.
Yeah, this is alarming. Gene therapy funding in the U.collapsed from eight point two billion dollars in twenty twenty-one to one point four billion in twenty twenty-four. funding for rare disease programs has dropped by double digits since twenty twenty-two. So you've got this convergence of reduced public funding and reduced private investment, right at a moment when the science is actually maturing.
What's driving the private investment pullback? Is it the I.uncertainty, or is there something else going on?
It's multiple factors. uncertainty is part of it — investors hate regulatory unpredictability. But there's also been a broader biotech downturn, higher interest rates making risky long-term investments less attractive, and some high-profile gene therapy commercial failures that spooked the market. When you combine all that with the specific orphan drug disincentives we've been discussing, it creates a pretty hostile environment for rare disease investment.
We're at this weird inflection point where the scientific capability has never been greater, but the financial and regulatory framework is arguably getting worse. That's not a great combination.
Which brings me to something that I think could be transformative, though it's also controversial. Commissioner Marty Makary has proposed a new regulatory pathway that would allow conditional approval of rare disease drugs based on what he calls a "scientifically plausible mechanism" rather than traditional randomized controlled trials. A draft guidance is under review at the Office of Management and Budget right now.
"Scientifically plausible mechanism" — that sounds like a dramatically lower evidence bar. What's the argument for it?
The argument is that for ultra-rare diseases — conditions affecting a few dozen or a few hundred patients — traditional randomized controlled trials are literally impossible. You can't randomize fifty patients into treatment and control arms and get statistically meaningful results. So the choice isn't between rigorous evidence and weaker evidence — it's between some evidence and no treatment at all. Under the plausible mechanism pathway, a drug could get conditional approval based on mechanistic plausibility and early clinical signals, with the requirement to collect real-world evidence post-approval.
The concern is that you're essentially approving drugs before you know if they work, and once they're on the market, the incentive to do rigorous follow-up studies is weak.
That's the risk. And it's not hypothetical — we've seen accelerated approval pathways for cancer drugs where confirmatory trials took years longer than promised, or never happened at all. But the counterargument is that rare disease patients and their families are willing to accept more uncertainty. If you have a child with a fatal genetic disease and there's a drug with a plausible mechanism and some early signals of efficacy, waiting five years for a definitive trial isn't really an option.
That's the ethical tension in its rawest form. And I don't think there's a clean answer. But I do think it's worth noting that the plausible mechanism pathway didn't come out of nowhere — it's a response to the reality that after forty-plus years of orphan drug incentives, ninety-five percent of rare diseases still have no approved treatment. The system is working better than it did in nineteen eighty-three, but it's not working well enough.
This is where I think the comparative policy analysis from that P.study is really instructive. models that combine push incentives — direct R and D support — with pull incentives like exclusivity have been more effective than individual policy tools alone. No single lever does the job. You need the tax credits and grants to reduce the upfront cost of development, and you need the market exclusivity and voucher programs to create a viable commercial endpoint. Remove either piece and the whole thing weakens.
Which makes the I.situation even more frustrating, because it's essentially breaking one piece of a carefully balanced system without thinking through the knock-on effect.
The knock-on effect are already visible. A forty-eight percent drop in second orphan designations isn't a theoretical concern — it's happening right now. Alnylam canceling a Stargardt disease trial isn't a hypothetical — it's a real decision with real consequences for real patients.
If you're a policymaker looking at this landscape, what's the actual to-do list? What moves the needle?
I think the evidence supports a few clear priorities. First, fix the I.orphan drug problem — either through the ORPHAN Cures Act or something similar. score of eight point eight billion over ten years is real, but it needs to be weighed against the innovation cost. Second, expand the voucher programs that are demonstrably working. The Rare Pediatric Disease voucher program has a track record now — forty-three diseases that had no treatment now have one. Third, invest in the unglamorous infrastructure — patient registries, natural history studies, diagnostic networks. Germany's twenty-five percent reduction in approval delays didn't come from changing exclusivity periods, it came from better data.
Fourth, I'd add — be honest about the trade-offs. The orphan drug story is impressive in some ways. Eight hundred approvals from a baseline of thirty-four. But it's also produced five-times-higher prices and a system where blockbuster drugs can capture orphan incentives. If we're going to have these programs, we should be willing to design them so the incentives actually flow to the diseases that need them, not to the indications that happen to qualify.
The indication-shopping problem is real, and it undermines the political sustainability of the whole framework. When voters see that Humira — a drug that treats millions of people for rheumatoid arthritis — is benefiting from orphan drug provisions, it erodes support for the programs that rare conditions depend on.
The political economy of this is tricky because the patients who need these drugs are, by definition, a tiny constituency. They don't have political power in the normal sense. The system works because of moral consensus and careful policy design, not because of electoral pressure. If that consensus frays, the whole thing could unravel.
One thing I want to circle back to — because I think it's the most promising near-term development — is the Commissioner's National Priority Voucher pilot. Sixty-one days for a gene therapy approval. That's not just fast, it's a proof of concept that the F.can move at the speed the science demands when the right incentives are in place. If they can replicate that for other ultra-rare conditions, it changes the calculus for investors and developers.
Though we should note that speed alone doesn't solve the fundamental problem. If you approve a drug in sixty-one days but it costs three point five million dollars and no insurance company wants to cover it, you haven't actually helped patients.
That's the access question, and it's where the European fragmentation problem becomes relevant to the U.Even with F.approval, patients can face months of insurance appeals, prior authorization requirements, and coverage denials. The drug exists, it's approved, but the patient can't get it.
The policy challenge isn't just "how do we get drugs developed" but "how do we get drugs developed, approved, priced sustainably, and actually into patients' bodies." And each of those steps has its own failure modes.
Which is why the registry and real-world evidence piece matters so much. If you can demonstrate that a drug is actually improving outcomes in the real world, that strengthens the case for coverage and reimbursement. It closes the loop between approval and access.
Alright, let me try to pull some of this together, because we've covered a lot of ground. The Orphan Drug Act was a genuine policy breakthrough — eight hundred approvals from thirty-four is not nothing. But the exclusivity provision that gets so much attention appears to be less important than the tax credits, grants, and fee exemptions, at least based on the Health Affairs data. The voucher programs are a targeted success story, especially for pediatric rare diseases. model offers lessons about the costs of fragmentation. And the I.has introduced a serious unintended consequence that's chilling multi-indication rare disease research.
The infrastructure play — registries, natural history studies, real-world evidence — is probably underrated relative to its impact. Germany's twenty-five percent reduction in delays is a concrete number that other countries should be paying attention to.
The plausible mechanism pathway is the wild card. If it's implemented thoughtfully, it could open up treatment possibilities for ultra-rare diseases that will never have traditional trials. If it's implemented poorly, it could erode evidence standards in ways that ultimately hurt patients.
I think that's right. And I'd add that the overall trajectory matters. We're at a moment where the science is advancing rapidly — gene therapy, R.therapeutics, precision medicine — but the policy framework is getting more complicated, not less. The countries that figure out how to align the scientific opportunity with smart incentive design are going to be the ones that actually deliver treatments to patients.
One last thing before we move on. You mentioned the gene therapy funding collapse — eight point two billion to one point four billion in three years. That's the kind of number that should be setting off alarm bells in every rare disease community. Because if the money disappears before the science matures, we're going to look back at this period as a massive missed opportunity.
funding dropping by double digits at the same time. The public and private pullback happening simultaneously is concerning. Rare disease research has always depended on this weird public-private hybrid model where government funds the basic science and companies fund the translation. If both sides are retreating, the pipeline dries up.
The question for the next five to ten years is whether the policy fixes we've discussed — the ORPHAN Cures Act, voucher reauthorization, the plausible mechanism pathway, better registry infrastructure — can offset the headwinds from reduced funding and increased regulatory uncertainty. I don't think we know the answer yet.
We don't. But the early signals — the forty-eight percent drop in second orphan designations, the Alnylam trial cancellation, the funding collapse — suggest that the headwinds are real and the policy response hasn't caught up yet.
And now: Hilbert's daily fun fact.
The average cumulus cloud weighs about one point one million pounds — roughly the same as two hundred adult elephants floating above your head.
If listeners want to take something practical away from this, here's where I'd land. If you or someone in your family is affected by a rare disease, the single most impactful thing you can do is participate in a patient registry. These registries are the foundation that everything else is built on — they help researchers understand the natural history of the disease, identify suitable trial populations, and make the case for investment. It's not glamorous, but it's important.
On the policy side, if this is something you care about, the ORPHAN Cures Act is the specific piece of legislation to watch. It's not a perfect solution, but it directly addresses the I.'s chilling effect on multi-indication rare disease research. Whether it moves forward will tell us a lot about where rare disease policy is headed.
The other practical point is that the voucher programs are up for reauthorization periodically, and they've been one of the few unambiguously successful policy tools in this space. When those reauthorization fights come up, the rare disease community needs to be loud.
I think the deeper takeaway is that there's no single fix. The countries that are doing this well — and the U.is still the leader, despite everything we've criticized — are the ones using multiple tools in combination. Tax credits plus exclusivity plus vouchers plus infrastructure investment. Take away any one piece and the whole thing gets weaker.
The orphan drug story is ultimately about whether we're willing to design markets that serve small populations, knowing that those designs will be imperfect and will sometimes be exploited. The alternative — letting the market alone decide — gave us thirty-four drugs in a decade. That's not acceptable. But neither is a system where drugs cost three point five million dollars and companies cancel rare disease trials to protect blockbuster franchises. The work is in the tension between those two failures.
That tension isn't going away. As we get better at identifying rare diseases and understanding their mechanisms, the number of potential drug targets is going to grow faster than our ability to fund and develop treatments for all of them. The prioritization questions are only going to get harder.
Thanks to our producer Hilbert Flumingtop for keeping this operation running. This has been My Weird Prompts. You can find every episode at myweirdprompts dot com or wherever you get your podcasts. If you've got a rare disease prompt of your own, send it our way.
We'll be back with more soon.
